EUVIMEDEUVIMED entdecken
Open Access

Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy

Rui Chen iD, Letao Xu iD, Alexander H Staudacher, Xing Wang, Ruoxuan Jia iD, John W Finnie, Xiaoyan Wang, Dawn M Whelan iD, Michael P Brown iD, Chun-Xia Zhao iD

Science Advances · 2026

DOI: 10.1126/sciadv.aed9568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Rui Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering, College of Engineering and IT, Adelaide University, Adelaide, SA, Australia. Hauptthemen laut MEDLINE: T-Lymphocytes, Cytotoxic, Nanoparticles, Immunotherapy, Tumor-Associated Macrophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health and Medical Research Council projects of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immunosuppressive tumor microenvironment (TME) remains one of the main obstacles that limit responsiveness to immunotherapy. Recently, lipid nanoparticles carrying messenger RNA (mRNA) have emerged as a promising strategy to modulate the immunosuppressive TME, with the ultimate goal of sustaining anticancer immunity of cytotoxic T lymphocytes (CTLs). However, there are challenges with mRNA-based cytokine/chemokine therapies such as the lack of specific targeting, low therapeutic efficacy, and elevated toxicity, raising concerns about their clinical translation. Here, we have developed an antibody-coated lipid nanoparticle (Ab-LNP) delivery system that targets the protein triggering receptor expressed on myeloid cells 2 (TREM2) expressed by tumor-associated macrophages (TAMs). We demonstrate that codelivery of a Toll-like receptor agonist and CXCL9-encoding mRNA encapsulated in our Ab-LNP successfully ameliorates immunosuppression and improves tumor infiltration and activity of CTLs. Further combination with immune checkpoint inhibitors against PD-L1 and CTLA-4 promoted a CTL-favoring immunological environment and durable memory immunity. Our Ab-LNPs targeting TAMs highlight the potential of reprogramming immunosuppressive TME to enhance CTL activity for improved response to cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, CytotoxicNanoparticlesImmunotherapyTumor-Associated MacrophagesRNA, MessengerLipidsNeoplasmsAnimalsTumor MicroenvironmentHumansMiceToll-Like Receptor AgonistsCell Line, TumorFemaleChemokine CXCL9Receptors, ImmunologicLiposomes

Substanzen

RNA, MessengerLipidsLipid NanoparticlesToll-Like Receptor AgonistsChemokine CXCL9Receptors, ImmunologicLiposomes

Autor:innen und Institutionen

  • School of Chemical Engineering, College of Engineering and IT, Adelaide University, Adelaide, SA, Australia.
  • Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and Adelaide University, Adelaide, SA, Australia.
  • School of Medicine, Adelaide University, Adelaide, SA, Australia.
  • Faculty of Health and Medical Sciences, School of Biomedicine, Adelaide University, Adelaide, SA, Australia.
  • Viral Immunology Group, Discipline of Surgery, Basil Hetzel Institute for Translational Medicine, Adelaide University, SA, Australia.
  • Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.

ORCID-Profile: Rui Chen, Letao Xu, Ruoxuan Jia, Dawn M Whelan, Michael P Brown, Chun-Xia Zhao

Förderung

  • National Health and Medical Research Council projects of Australia

Zitieren

APA

Chen, R., Xu, L., Staudacher, A. H., Wang, X., Jia, R., Finnie, J. W., Wang, X., Whelan, D. M., Brown, M. P., & Zhao, C. X. (2026). Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy. Science Advances. https://doi.org/10.1126/sciadv.aed9568

Vancouver

Chen R, Xu L, Staudacher AH, Wang X, Jia R, Finnie JW, et al. Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy. Science Advances. 2026. doi:10.1126/sciadv.aed9568

BibTeX
@article{Chen2026,
  author = {Chen, Rui and Xu, Letao and Staudacher, Alexander H and Wang, Xing and Jia, Ruoxuan and Finnie, John W and Wang, Xiaoyan and Whelan, Dawn M and Brown, Michael P and Zhao, Chun-Xia},
  title = {Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aed9568}
}
Kostenlos starten →